Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Biogen Analysts Slash Their Forecasts After Q3 Results
01:28pm, Thursday, 31'st Oct 2024
Biogen Inc BIIB reported upbeat earnings for the third quarter on Wednesday.
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarke
Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
03:06pm, Wednesday, 30'th Oct 2024
BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.
Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript
12:49pm, Wednesday, 30'th Oct 2024
Biogen Inc. (NASDAQ:BIIB ) Q3 2024 Earnings Call Transcript October 30, 2024 8:30 AM ET Company Participants Stephen Amato - Senior Director of IR Chris Viehbacher - President and CEO Priya Singhal -
Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say
10:36am, Wednesday, 30'th Oct 2024
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compar
Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
09:06am, Wednesday, 30'th Oct 2024
Biogen Inc. (BIIB) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.77 per share. This compares to earnings of $4.36 per share a year ago.
Biogen's stock pops after earnings top estimates and company raises guidance
07:47am, Wednesday, 30'th Oct 2024
“We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline,” the company's CEO said.
Biogen lifts annual profit forecast as cost cuts help
06:54am, Wednesday, 30'th Oct 2024
Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures helped make up for falling sales of its multiple sclerosis medicines.
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
06:50am, Wednesday, 30'th Oct 2024
Biogen reported third-quarter revenue and adjusted earnings that topped expectations. The company also raised its full-year profit guidance.
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Biogen Inc. (NASDAQ: BIIB) on be
CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degrade
Biogen Prepares for Q3 Earnings Call
01:22pm, Monday, 28'th Oct 2024
Biotechnology firm Biogen Inc (NASDAQ:BIIB) is scheduled to report third-quarter results before the open on Wednesday, Oct. 30.
Seeking Clues to Biogen (BIIB) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:20am, Monday, 28'th Oct 2024
Evaluate the expected performance of Biogen (BIIB) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Biogen appoints insider as CFO after Michael McDonnell to retire next year
09:05am, Monday, 28'th Oct 2024
Biogen said on Monday insider Robin Kramer would take over as its chief financial officer after Michael McDonnell plans to retire from the post in February 2025.
CAMBRIDGE, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 mo
